ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0106

A Systematic Review of Racial and Ethnic Disparities in Disease Related Outcomes Among Patients with SLE

Teresa Semalulu1, Keerthana Pasumarthi1, Kevin Zhao1, Rauda AlDhaheri1, Nadine Akbar2, KAREN BEATTIE1 and KONSTANTINOS TSELIOS3, 1McMaster University, Hamilton, ON, Canada, 2Humber River Hospital and University of Toronto, Toronto, ON, Canada, 3McMaster University, Population Health Research Institute, Hamilton, ON, Canada

Meeting: ACR Convergence 2022

Keywords: Disparities, Mortality, Nephritis, race/ethnicity, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Healthcare Disparities in Rheumatology Poster

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Racialized patients and ethnic minorities have worse outcomes in SLE. This is likely related to a complex interplay between genetic and non-genetic factors. Numerous studies have examined racial and ethnic disparities in SLE, with no comprehensive summary of disease-related outcomes and health care utilization among these patients. The objective of this study is to perform a systematic review describing racial and ethnic disparities in the following disease-related outcomes among adult patients with SLE: (1) mortality, (2) end-stage renal disease (ESRD), (3) disease-related damage, (4) cardiovascular disease, (5) malignancy, and (6) hospital utilization.

Methods: The systematic review protocol was registered with PROSPERO. A systematic search of the scientific literature was performed using three databases (OVID Embase, OVID Medline and Web of Science) to obtain articles published before October 2021. Search terms included the outcomes of interest (i.e., mortality, ESRD, disease-related damage, cardiovascular disease, malignancy and hospital utilization) and variations of terms used to describe racial and ethnic groups (e.g., White, Black, Asian, Hispanic, Indigenous). Longitudinal observational studies with a minimum of two years of follow-up were included. Case series, systemic reviews, and interventional studies were excluded. Screening of titles, abstracts and full-text articles were performed in duplicate by four independent reviewers (TS, KP, KZ, RA). Data extraction and synthesis were performed.

Results: The systematic literature search yielded 5528 titles and abstracts, of which 191 studies were selected for full-text review. Further review yielded 127 studies for inclusion (Figure 1). The majority of studies were conducted in North America (n=99), followed by Europe (n=16), Australia (n=7), Africa (n=6), Asia (n=6) and South America (n=3). Racial and ethnic groups identified include Whites (n=122), Blacks (n=133), Asians (n=51), Indigenous peoples (n=20), Hispanics (n=48) and others (n=6).

A total of 102 studies (80%) reported worse outcomes among racial and ethnic minority groups. Disparities were most commonly identified in studies describing outcomes among Black (n=93) and Hispanic (n=37) patients. Most studies reported outcomes related to mortality (n=60), with 52 (87%) reporting worse outcomes among racialized groups. Of 30 studies reporting on the development of ESRD, 26 (87%) identified racial and ethnic disparities. Worse outcomes were also reported among studies examining disease-related damage (n=30), cardiovascular disease (n=9), hospitalization (n=8), and malignancy (n=8) (Table 1).

Conclusion: This comprehensive review highlights the higher reported rates of mortality, ESRD, disease-related damage, cardiovascular disease, malignancy and hospitalization, among racial and ethnic minority patients with SLE. In the absence of a biological explanation for these difference, it is prudent to identify and address systemic causes for these outcomes. A meta-analysis of these outcomes is currently underway.

Supporting image 1

Figure 1: PRISMA flow diagram

Supporting image 2

Table 1: Summary of included studies


Disclosures: T. Semalulu, None; K. Pasumarthi, None; K. Zhao, None; R. AlDhaheri, None; N. Akbar, None; K. BEATTIE, None; K. TSELIOS, AstraZeneca, GlaxoSmithKlein(GSK).

To cite this abstract in AMA style:

Semalulu T, Pasumarthi K, Zhao K, AlDhaheri R, Akbar N, BEATTIE K, TSELIOS K. A Systematic Review of Racial and Ethnic Disparities in Disease Related Outcomes Among Patients with SLE [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/a-systematic-review-of-racial-and-ethnic-disparities-in-disease-related-outcomes-among-patients-with-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-systematic-review-of-racial-and-ethnic-disparities-in-disease-related-outcomes-among-patients-with-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology